Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer

Morgan Stanley Downgrades Bristol-Myers Squibb Co. (BMY) to Equalweight

Morgan Stanley downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Overweight to Equalweight.

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $75.32 yesterday.

Deutsche Bank Comments on Bristol-Myers Squibb (BMY) Opdivo News; Analyst Says Merck (MRK) Not Guaranteed to be Alone in Front-Line Setting

Deutsche Bank analyst Gregg Gilbert commented on Bristol-Myers Squibb (NYSE: BMY) and Merck (NYSE: MRK) following news BMY's Opdivo failed to meet the primary endpoint for CHECKMATE-026. In his view, the news is clearly positive for Merck and negative for Bristol-Myers, but he said Merck is not guaranteed to be alone in the front-line setting.

"We need more time to fully assess the implications of this move and thus are not changing our ratings or estimates here (both rated Hold), but... More

Bristol-Myers (BMY) Opdivo Trial Miss a 'Seismic Event', BMO Capital Says (MRK)

BMO Capital analyst Alex Arfaei weighed in on Bristol-Myers Squibb Co. (NYSE: BMY) after the company announced that announced that in CheckMate-026 (CM-026), a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Opdivo did not meet the trial's primary endpoint of progression-free survival (PFS) in patients expressing PD-L1 >= 5%. Arfaei calls this a significantly negative for BMY and positive for Merck (NYSE:... More

SunTrust Robinson Humphrey Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral

SunTrust Robinson Humphrey downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Neutral with a price target of $68.00 (from $86.00).

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click... More

Bristol-Myers Squibb (BMY) Falls 22% After Shares Resume Trading

Bristol-Myers Squibb (NYSE: BMY) Falls 22% After Shares Resume Trading

Merck (MRK) Surges After Bristol-Myers Squibb's (BMY) CheckMate -026 Trial Fails

(Updated)

Shares of Merck (NYSE: MRK) surged pre-market Friday after Bristol-Myers Squibb (NYSE: BMY) released disappointing results from CheckMate -026, phase 3 study of Opdivo for treatment of patients with NSCLC.

The study showed Opdivo did not meet trial... More